PTCT ▼ -0.2% - PTC Therapeutics, Inc. $PTCT PTCT - PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy PTC Therapeutics completed its acquisition of ST-920, a gene therapy candidate for Fabry disease, though the stock moved modestly lower with a 0.2% decline today. The acquisition expands PTC's pipeline in rare genetic diseases, though market reaction suggests investors may be digesting the financial terms or waiting for further clinical developments. 21-SEP-2026 04:30 PM ET